Nanofibrous drug delivery systems for breast cancer: a review

Nanotechnology. 2021 Dec 13;33(10). doi: 10.1088/1361-6528/ac385c.

Abstract

Breast cancer is the most common type of cancer among women. Breast-conserving surgery (BCS) is one of the preferred approaches for treating non-invasive or early-stage breast cancers. However, local-regional recurrence (LRR) is one of the critical risk factors after BCS. As many as 10%-20% of BCS cases may show LRR within 5 years and almost 50% within 10 years after surgery. Radiation therapy is one of the preferred treatments used to prevent LRR after BCS. However, because of possible side-effects of radiation therapy, targeted drug delivery systems (DDS) based on nanofibers loaded with anti-cancer drugs have been explored in recent years to control LRR. This paper aims to review different polymers and anti-cancer drugs used for developing nanofibrous DDS against various breast cancer cell lines for their efficacy and advantages. It was observed that the utilization of nanofibers scaffolds after mastectomy could decrease the recurrence of breast cancer cells to a great extent as these nanofibrous scaffolds release drugs in a sustained manner for a prolonged time eliminating the need for radiations. Besides, the side effects of chemotherapy or other aggressive anticancer treatment on healthy cells could also be avoided.

Keywords: breast cancer; drug delivery; nanofibers; nanomedicine.

Publication types

  • Review

MeSH terms

  • Animals
  • Breast Neoplasms / drug therapy*
  • Drug Delivery Systems*
  • Female
  • Humans
  • Mice
  • Nanofibers* / chemistry
  • Nanofibers* / therapeutic use
  • Nanomedicine*